D&O Insurance for Biotech Startups
Protect Your Personal Assets and Close Your Round With Confidence
Index
Gordon B. Coyle
CEO, The Coyle Group
845-474-2924
How to get started
TL;DR. Executive Summary
D&O insurance for biotech startups protects your directors, officers, and often the company itself from claims tied to management decisions, fundraising disclosures, and alleged misstatements.
Here is what matters most:
Biotech founders raise outside capital, make forward-looking statements about pipelines and timelines, and sit on boards that make high-stakes calls with real money on the line. That combination is exactly what draws lawsuits, and it is exactly why serious investors treat directors and officers coverage as a condition of the deal, not a nice-to-have.
The problem is that most founders learn this the week of closing, get a quote that feels punishing, and buy whatever binds fastest. That is how you end up with a policy that looks fine on paper and leaves a gaping hole where your biggest life-sciences exposures live.
The Coyle Group works on the complex, high-value risks that other agencies do not know how to structure. D&O for a clinical-stage company is one of them.
Why founders come to us:
You need D&O because an investor is requiring it or a board seat depends on it, and you want it structured so it actually responds when a trial disappoints or a disclosure gets challenged. We build the program around your funding stage and your science, not a generic tech template, and we have structured management liability for founders, funds, and boards for 40 years. The fastest next step is a short call before your round closes.
Why Do Biotech Startups Need D&O Insurance?
Biotech startups need D&O insurance because they raise outside money, hit public regulatory milestones, and make forward-looking claims that can trigger investor, employee, or regulator lawsuits if results disappoint. The less obvious risk sits closer to home: without it, a claim can reach a founder’s personal assets when the company cannot indemnify them, and that gap is where most first-time founders get hurt.
Here is the cost of getting it wrong. Life-sciences companies made up about 20.2% of all U.S. securities class-action filings in 2023, with 43 complaints in a single year, according to Dechert’s survey of securities fraud class actions against U.S. life sciences companies. Defense costs alone commonly run into the low-to-mid millions before liability is ever proven. For a company burning cash toward the next milestone, one uninsured suit can end the story.
Why biotech draws more fire than most sectors:
The reader’s true goal here is rarely to learn about D&O. It is to protect the founder and the company so the round closes and a bad quarter does not become a personal bankruptcy. That is the job D&O insurance for biotech startups is built to do, and it is why the coverage shows up as a gating item in so many term sheets.
A few patterns we see repeatedly with early founders:
Not sure whether your current program leaves that gap open? Contact us for a no-obligation review.
What Does D&O Insurance for Biotech Startups Actually Cover?
D&O insurance for biotech startups covers legal defense costs, settlements, and judgments arising from claims that directors or officers committed a wrongful act: mismanagement, breach of fiduciary duty, misleading investors, or failure to supervise. The nuance founders miss is that D&O is really three coverages in one policy, and which part responds depends entirely on whether the company can indemnify you.
Most policies are built in three sides, and each one protects a different party:
Typical claims a biotech D&O policy is designed to answer include:
For a company moving through financing rounds, both individual and corporate exposure show up at the same time, which is why the Side A, B, and C balance matters so much. You can see how D&O sits alongside other management liability lines on our insurance by coverage hub.
What Actually Triggers a D&O Claim at a Biotech Startup?
Most biotech D&O claims trace back to a short list of public events: an FDA Complete Response Letter, a clinical hold, a missed primary endpoint, a safety signal, or a statement made around a financing or IPO. The trigger founders underestimate is timing, because the lawsuit usually follows the stock or valuation drop, not the science itself.
The events that most often turn into a claim, and the allegation that tends to follow each:
This pattern is well documented. In 2023, about 46.5% of life-sciences securities suits alleged misrepresentations about product efficacy or safety and about 27.9% alleged regulatory or FDA-timing misstatements, according to Dechert. Settlements are climbing too: the average securities class-action settlement rose roughly 27% to about $56 million in the first half of 2025, per Cornerstone Research data. Those are the numbers a single triggering event can put in play once a claim is filed.
Real-World Example: A Trigger in Action
When Replimune received an FDA Complete Response Letter in 2025, its shares fell roughly 75% and investors filed a securities class action alleging the company had overstated the likelihood of approval. The science question and the securities question are separate. D&O responds to the second, defending the board and officers regardless of how the underlying trial question is ultimately resolved.
What Does D&O Insurance NOT Cover for Biotech Companies?
D&O insurance does not cover bodily injury, property damage, or ordinary product-failure claims, and it typically excludes fraud, deliberate criminal acts, and unlawful personal profit. The trap for biotech founders is assuming D&O handles their science risk. It does not, and that misunderstanding is how companies discover a coverage gap at the worst possible moment.
D&O insurance for biotech startups is management liability, not operational liability.
For a life-sciences company, that means these exposures need their own policies:
Warning: The Generic Tech-Policy Trap
A biotech that buys a generic tech-startup D&O policy often inherits exclusions written for software companies, including language that fights with CRO contracts and clinical exposures. The policy binds, everyone relaxes, and the real risk stays wide open.
This is the single most common structural error we see. If you want a clear read on what your current D&O policy quietly leaves out, that is exactly the kind of review we run.
Contact us and we will pressure-test the wording of your current policy at no charge.
How Much Does D&O Insurance for Biotech Startups Cost?
D&O insurance for biotech startups typically costs about $5,000 to $10,000 per year for $1 million in limits at the startup stage, with biotech landing toward the higher end when there are investors, a board, and elevated regulatory risk. The figure most founders fixate on is the premium; the number that actually matters is what a single uncovered claim would cost, which reframes the whole conversation.
Rough market ranges to set expectations:
Company Profile |
Typical Annual Premium (per $1M limit) |
|---|---|
|
Very small private, minimal risk |
$500 – $3,000 |
|
Early tech startup |
$4,000 – $7,000 |
|
Venture-backed biotech startup |
$5,000 – $10,000+ |
|
Later-stage / pre-IPO clinical company |
$10,000+ and rising with limits |
As a rule of thumb, a venture-backed biotech pays roughly 25% to 50% more than a comparable non-life-sciences tech startup at the same stage, and that gap widens at clinical and pre-IPO stages where regulatory and offering exposure climbs.
What drives a biotech quote up or down:
Set against a defense bill that runs into the millions, a five-figure premium is not the expensive number in the room. Reframe the “this quote is insane” reaction around the claim it is designed to absorb.
Real-World Example: What No D&O Looks Like
A pre-revenue, clinical-stage startup had a seed round paused when the lead investor found there was no D&O in place. Once a $3 million program with a strong Side A was structured through a specialized broker, the close proceeded. The founders paid close attention to exclusions around clinical-trial claims and CRO contract language, because the generic quote they first received would have left those exposures open. The life-sciences premium ran meaningfully higher than a non-biotech peer, and it was still a rounding error next to the round it unblocked.
Book a Call and we will build a stage-appropriate estimate around your raise, not a generic one.
When Should a Biotech Startup Buy D&O Insurance?
A biotech startup should buy D&O insurance before its financing round closes, especially when an investor or incoming board member requires it as a condition of the deal. The detail founders overlook is that coverage timing and the policy’s retroactive date can determine whether an early decision is protected at all, so binding late can leave a silent gap even after you buy.
The honest exception: a pre-incorporation solo founder with no outside capital, no board, and no employees can usually wait, because the exposure really begins with your first investor or independent director. The moment any of those three appears, so does the need for coverage.
Practical timing guidance:
The reason “when do we need D&O” shows up in nearly every founder forum is that timing is tied to events, not the calendar: a term sheet, a board seat, a new institutional investor. When one of those lands, the clock is already running. If you have a close on the horizon, do not let coverage be the item that stalls it.
Contact us early and we will have your D&O ready to bind before your close date.
How Much D&O Coverage Do Biotech Startups Need?
Most biotech startups need somewhere between $2 million and $5 million in D&O limits at the seed stage, scaling to $5 million to $25 million as they approach later clinical phases, offerings, or an IPO. The subtlety is that the “right” limit is driven less by company size and more by investor requirements and litigation exposure, which is why two similar-looking startups can carry very different towers.
General limit benchmarks by stage:
Stage |
Common D&O Limit Range |
|---|---|
|
Pre-seed / seed |
$2M – $5M |
|
Series A / early clinical |
$5M – $10M |
|
Later clinical / pre-IPO |
$10M – $25M+ |
How to think about the number you actually need:
Because financing and clinical events move the target, these limits should be reviewed as a living number, not set once. You can see where D&O fits within a full life sciences insurance program on our industry hub.
Book a Call for a limit recommendation tied to your cap table and stage.
How Do You Structure a Strong D&O Program for a Biotech Startup?
You structure a strong biotech D&O program by matching limits to your stage, securing a robust Side A for individual directors, and stripping out life-sciences exclusions that a generic policy would leave in. The part founders rarely evaluate is the fine print around clinical trials, CRO contracts, and regulatory investigations, and that wording is often what decides whether a claim is paid or fought.
What to look for when you compare programs:
The founders who negotiate these terms in the term sheet, deciding who pays the premium and what limits are required, avoid the scramble at closing. A specialized broker keeps a mis-specified program from triggering delays with investors or CROs. This is precisely the complex, high-value risk structuring The Coyle Group was built for.
The Coyle Group structures biotech D&O programs from seed through pre-IPO. Contact us to have your program reviewed line by line.
How Does D&O Fit With the Rest of a Biotech Startup’s Insurance Program?
D&O insurance for biotech startups is the management-liability layer of a much larger program, and it works only when the coverages around it are in place to catch the risks D&O deliberately excludes. The point founders miss is that a claim rarely arrives in one neat category, so a gap between two policies is where a supposedly covered loss quietly falls through.
The lines that catch what D&O deliberately leaves out are product and clinical liability, professional liability, employment practices coverage, and cyber liability for the sensitive research and patient data you hold. The risk is not any single policy; it is the seams between them.
Why this matters for a growing company:
Structuring D&O insurance for biotech startups alongside these lines, so they reinforce rather than contradict each other, is the difference between a program that looks complete and one that responds. You can see how these coverages map across a full vertical on our insurance by industry hub, and how each coverage type is defined on our insurance by coverage hub.
To have the entire stack reviewed as one connected program, book a call with The Coyle Group.
What Does Uninsured D&O Risk Actually Look Like for a Biotech Founder?
Uninsured D&O risk rarely arrives as one dramatic event. It shows up as a stalled financing, a lawsuit after a disappointing readout, or a co-founder dispute that names the board, each landing on the founder’s personal balance sheet. The scenarios below are composites drawn from common biotech claim patterns, not specific clients, and each shows where a well-structured policy changes the outcome.
The seed round that stalled.
A first-time founder lines up a lead investor. In final diligence, the investor’s counsel asks for proof of D&O with Side A before wiring funds, and there is none in place. The close slips several weeks while coverage is sourced and negotiated, burning runway and goodwill at the worst moment. With a stage-appropriate program bound before the term sheet was signed, the same round would have closed on schedule. This is the “the investor won’t close without D&O” problem founders describe over and over.
The readout that became a lawsuit.
A clinical-stage company guides investors toward a Phase 2 readout. The primary endpoint misses, the valuation falls, and an investor group alleges leadership overstated the odds and downplayed a known risk. Defense costs climb into seven figures long before any liability is decided. A D&O tower with strong Side A absorbs those costs and shields the founders’ personal assets. Without it, the bills hit a thin balance sheet and, through indemnity gaps, the founders themselves.
The pre-revenue dispute nobody planned for.
Two co-founders split before the company earns a dollar of revenue. One alleges the board forced them out improperly and sues the remaining directors. Many founders assume a pre-revenue company has no D&O exposure, and this is exactly the claim D&O with EPLI is built to answer. Without it, the surviving founder funds the defense personally, precisely when cash is tightest.
The common thread across all three is that the loss is rarely the premium. It is the uninsured event that arrives while the company is least able to absorb it, from “who defends us if a trial fails” to “the board members won’t join without Side A.” Each of these is a real question biotech founders ask before they have coverage in place.
Questions About D&O Insurance for Biotech Startups
Get the Right Biotech D&O Coverage
The Coyle Group has been structuring commercial insurance programs for business owners for over 40 years. Gordon B. Coyle, CPCU, ARM, AMIM, PWCA, built this practice around one belief: business owners deserve the same clarity and rigor in their insurance decisions that they apply to every other part of their business.
When it comes to D&O insurance for biotech startups, we understand that a clinical-stage company’s risk profile is unlike any other client. You are making public statements about science and timelines, raising outside capital, and managing an investor board from day one. We structure coverage that accounts for all of it, and for the life-sciences exclusions a generic policy would leave open.
Whether you are approaching a seed round or preparing for a later raise, the time to build your coverage is before the close. We work directly with your legal and financial advisors to ensure your D&O and full insurance program are in place when you need them. Contact us or book a call to get started.
This article was written by the CEO of The Coyle Group, Gordon B. Coyle, CPCU, ARM, AMIM, PWCA, who has over 40 years of experience working with business owners of all sizes and industries across the US, solving their insurance challenges.
Here’s how to take the next step
Schedule Your Insurance Confidence Assessment
In our 30-minute call, you’ll discover:
Not ready for a call?
Get Free Access to Our Gated Video:
“How to Finally Feel Confident in Your Coverage. “
And discover the exact system we use to help business owners eliminate hidden coverage gaps, stop overpaying, and finally feel confident in their protection.
What Peace of Mind Looks Like
Trusted by business owners across the U.S.
The Coyle Group is 1st class! Gordon and his team are knowledgeable, responsive, and attentive to detail. Gordon is that rare breed of professional who genuinely cares for his clients and works hard to exceed their expectations. I highly recommend them.
The insurance brokerage service was truly tailored to my needs, nothing like those big brokers who steer you toward random policies that don’t fit your profile. Thank you to the team for your help.
I was working with another broker and having difficulty acquiring General Liability coverage. A colleague recommended The Coyle Group. They were able to get coverage bound in just a couple of business days and a policy issued in ten days, and with a solid carrier at a competitive premium. Truly impressive results, plus it was a pleasure working with them. I highly recommend the Coyle Group!
If any business is looking to work with an insurance brokerage firm that is not only excellent at what the firm does, but one that deeply values the needs of the clients, then The Coyle Group is the firm for you. Give them a call and see for yourself. I can assure that you will quickly agree.
Want to know more?
See related blogs
Protecting Non-Profit Board Members with D&O Insurance
Rippling PEO Review: EPLI Coverage Risks Explained
The Ultimate Guide to D&O Insurance: Everything You Need to Know in 2025
